Rapid recognition and treatment shown to be effective for lung disease in patients given new drug for advanced cancer

Newswise – (New York, NY – August 11, 2022) – According to a study published in ESMO Open on August 11, 2022.

Using data from nine clinical trials, this study provides one of the most comprehensive reviews of the diagnosis and treatment of interstitial lung disease in patients who received an antibody-drug conjugate known as T-DXd, a class of drugs designed as a targeted therapy for the treatment of cancers. .

The retrospective review looked at 1,150 heavily pretreated patients with breast, lung, gastric, colorectal or other cancers in nine studies treated with T-DXd, also known as ENHERTU®.

“Interstitial lung disease (IPD) is a known risk factor in patients treated with antibody-drug conjugates for cancer,” said lead author Charles Powell, MD, MBA, Janice and Coleman Rabin Professor of Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine. at the Icahn School of Medicine at Mount Sinai. “Using lessons learned from early clinical trial experience, physician training and patient management protocols were revised and disseminated by study sponsors. More recent trial data in the front lines treatment regimens demonstrated lower rates of PID events, suggesting that close monitoring and proactive management of PID/pneumonia is warranted for all patients.

The researchers looked at data from four phase 1 studies and five phase 2 studies of T-DXd, where patients received different doses of cancer treatment every three weeks. The research team also reviewed data from an independent clinical review board, chaired by Dr. Powell, which reviewed clinical information and chest CT imaging of all clinical trial patients with suspected lung disease. drug-related interstitial tissue, which may lead to pulmonary fibrosis.

Among patients who were previously heavily treated with other cancer therapies, the analysis found that 15.4% (grade 1 or 2, 77.4%; grade 5, 2.2%) had lung disease interstitial, with low-grade symptoms usually occurring within the first 12 months. —after treatment with T-DXd.

Interstitial lung disease is a known risk of several cancer therapies, including T-DXd, which can be serious, life-threatening, or fatal. The results of these studies suggest that close monitoring and proactive management can reduce the risk of PID, and that patient awareness and ongoing education can contribute to early detection.

This study was sponsored by pharmaceutical company AstraZeneca and Daiichi Sankyo. Experts from Memorial Sloan Kettering Cancer Center in New York; Aichi Cancer Center in Nagoya, Japan; Cancer Institute Hospital of JFCR in Tokyo, Japan; Netherlands Cancer Institute in Amsterdam, Netherlands; Università Degli Studi di Milano in Milan, Italy; Niguarda Cancer Center in Milan, Italy; National Taiwan University Hospital in Taipei City, Taiwan; and the University of Colorado Cancer Center in Aurora, Colorado, contributed to this research.

About Mount Sinai Health System

The Mount Sinai Health System is one of the largest academic medical systems in the New York metropolitan area, with more than 43,000 employees working in eight hospitals, more than 400 outpatient practices, nearly 300 laboratories, a nursing school and a large school of medicine and higher education. Mount Sinai advances health for everyone, everywhere, by addressing the most complex health challenges of our time – discovering and applying new knowledge and scientific knowledge; developing safer and more effective treatments; train the next generation of medical leaders and innovators; and supporting local communities by providing high quality care to all who need it.

Through the integration of its hospitals, laboratories and schools, Mount Sinai offers comprehensive healthcare solutions from birth to geriatrics, leveraging innovative approaches such as artificial intelligence and IT while keeping patients’ medical and emotional needs at the center of all treatments. The health system includes approximately 7,300 primary and specialty care physicians; 13 joint venture day surgery centers in the five boroughs of New York, Westchester, Long Island and Florida; and over 30 affiliated community health centers. We are regularly ranked by US News and World Report‘s Best Hospitals, receiving a high “Honor Roll” status, and are highly ranked: #1 in Geriatrics and top 20 in Cardiology/Cardiac Surgery, Diabetes/Endocrinology, Gastroenterology/Gastrointestinal Surgery, Neurology/Neurosurgery, orthopaedics, pulmonology/lung Surgery, rehabilitation and urology. New York Eye and Ear Infirmary of Mount Sinai is ranked #12 in ophthalmology. US News and World ReportMount Sinai Kravis Children’s Hospital’s “Best Hospitals for Children” ranking ranks among the best in the nation in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that has distinguished itself by several indicators: it is consistently ranked in the top 20 by US News and World Reports “Best Medical Schools,” aligned with a US News and World Report “Honor Roll” Hospital, and among the top 20 in the nation for funding from the National Institutes of Health and among the top 5 in the nation for many areas of basic and clinical research. Newsweek’s “World’s Best Smart Hospitals” ranks Mount Sinai Hospital number one in New York and among the top five in the world, and Mount Sinai Morningside in the top 20 globally.

For more information visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Comments are closed.